Eli Lilly Plans Four New U.S. Manufacturing Sites After $50B Investment
Eli Lilly plans to more than double its U.S. manufacturing investments since 2020, surpassing $50 billion, building four new pharmaceutical sites across the country. Three will focus on API manufacturing and one will expand parenteral injectable production, including locations in North Carolina and Indiana. The expansion is expected to create 3,000+ high-skilled jobs and strengthen supply-chain resilience for FDA-approved medicines worldwide.